Trials / Terminated
TerminatedNCT05127174
Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms
A Phase I/II Trial of Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the effectiveness and safety of fedratinib as maintenance therapy in participants with myeloproliferative neoplasms (MPNs) after allogeneic hematopoietic cell transplant (HCT).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fedratinib Pill | Fedratinib is taken orally once per day, in 100 mg capsules. Fedratinib is an oral kinase inhibitor with activity against wild type and mutationally activated Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). |
Timeline
- Start date
- 2022-03-14
- Primary completion
- 2025-01-03
- Completion
- 2025-01-03
- First posted
- 2021-11-19
- Last updated
- 2025-12-04
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05127174. Inclusion in this directory is not an endorsement.